Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression Therapy

Part of paid clinical trials in Stanford, California.

Sponsor
Stanford University
Study ID
NCT00003716
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
3 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of rituximab in treating patients who have lymphoproliferative disorder that is associated with immunosuppression therapy.

Key Dates

Start date
Mar 31, 1998
Status verified
May 2022
Primary completion
Jan 31, 2007
Completion
Jan 31, 2007

Study Design

Enrollment
25 participants (actual)
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford University Medical CenterStanfordCalifornia94305-5408-

Find similar trials in Stanford, CA

By research site
Stanford University Medical Center· Stanford, CA

Related Studies